Canada · Advertising framework
Advertising prescription medicines on websites in Canada
General market orientation, not campaign clearance. Research scope and dates
Product and service rules
Start with Canadian market authorisation
Regulator guidance
Advertising eligibility depends on the product’s Canadian regulatory status and authorised uses. Health Canada describes independent preclearance as generally voluntary, with specific exceptions such as opioid advertising; do not label every campaign as legally subject to mandatory preclearance.
Sources: Advertising requirements for drugs and medical devices
Consumer prescription-drug representations are tightly limited
Regulator guidance
C.01.044 limits prescription-drug consumer advertising representations to the drug’s brand, proper or common name, price and quantity. Do not import the US product-benefit DTC model. A disease-awareness message that links to a product may still be promotional and requires a separate assessment.
Sources: Distinction between advertising and other activities: legislative and regulatory provisions
Channel rules
Check the complete consumer-facing message
Regulator guidance
Competition Act provisions address materially false or misleading promotion of products, services and business interests. The assessment considers literal meaning and general impression, including images and omitted conditions. Review professional titles, claimed outcomes and conditional prices with the same care as the headline.
Sources: False or misleading representations
Quebec: review French content and signage separately
Regulator guidance
Applies when: Quebec commercial-language rules apply to the business and execution.
Businesses operating in Quebec must provide French commercial publications, including a complete French website and French social-media content, subject to applicable exceptions. Public signage and commercial advertising have a distinct French-predominance regime. Review the rules effective from 1 June 2025 for trademarks and business names on signage; a bilingual website alone does not resolve an exterior sign.
Sources: French-language rights in commerce; Business names and trademarks on signage
Review the whole website journey
Editorial recommendation
Review the product card, metadata, testimonials, booking page and checkout together. Archive the published version and check third-party widgets after updates.
Campaign workflow
Prescription Medicines: prepare the review
Editorial recommendation
Identify the exact authorised medicine and prescription status. Resolve the public-promotion restriction or permitted route before developing creative. Separate medicine promotion from neutral disease information and healthcare-service advertising.
Keep a traceable campaign decision
Editorial recommendation
Keep one review record linking the offer, local market status, claim evidence, exact creative, media settings and any regulatory or professional clearance. Record who checked each condition. Reopen the review when the offer, claim, source rule or execution changes.
Pre-publication checklist
- Identify the exact authorised medicine and prescription status.
- Resolve the public-promotion restriction or permitted route before developing creative.
- Separate medicine promotion from neutral disease information and healthcare-service advertising.
- Record product or provider eligibility before approving claims.
- Archive the final creative and its evidence, permissions and review decisions.
- Assign an owner for source updates, complaints and prompt withdrawal of inaccurate material.
Scope and unresolved questions
- Ontario physician and dental guidance and Quebec commercial-language requirements are documented. Other provinces/territories, pharmacy rules and health-information statutes remain outside this targeted review. CASL permission does not itself authorise use of clinical records for marketing.
- This national baseline does not review every broadcaster rule, platform policy, regional licensing condition, promotion mechanic or data-transfer arrangement. No format-specific warning dimensions or durations should be inferred where none are supplied.
Research scope, introduction and dates
Prescription-medicine advertising on websites in Canada starts with a legal eligibility decision. Establish whether the proposed consumer message is permitted, restricted to limited information or confined to a professional route before developing benefit and risk statements.
On a website, the headline, product card, testimonial, embedded video and booking or checkout page all contribute to the message. Follow the rules below across that journey, rather than reviewing the landing-page text in isolation.
General market orientation, not legal, regulatory or medical advice, a complete compliance plan or clearance of an advertisement. Actual requirements depend on the specific offer and campaign.
How to use this national baseline
Editorial overview
This framework combines researched national rules with editorial review steps. Federal health-product and competition-law baseline; provinces, territories and Quebec language requirements need local checks. A visible channel workflow does not establish that the selected product or service may be advertised there. Read the category restrictions first.
The review date identifies when the cited provisions or regulator excerpts were checked. It does not mean that every local rule, exception, professional standard or platform policy has been reviewed.
Sources
- Advertising requirements for drugs and medical devices
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
- Distinction between advertising and other activities: legislative and regulatory provisions
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
- False or misleading representations
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
- French-language rights in commerce
Follow-up review of the cited issue on 25 October 2026; scope and remaining conditions are recorded in the modules and review register.
- Business names and trademarks on signage
Follow-up review of the cited issue on 25 October 2026; scope and remaining conditions are recorded in the modules and review register.
From framework to action
Local expertise in Canada
Find support with medical and health marketing, marketing and sales advice, or organizing your business and coordinating projects in Canada.
Medical & health marketing
No partners listed in this category yet.
Marketing & sales advisory
No partners listed in this category yet.
Business & project coordination
No partners listed in this category yet.
Join the local partner directory
Would you like your company to be listed?
Talk to us about the terms of a listing. Leave your details and we will get in touch.